Ovarian transitional cell carcinoma
diseaseOn this page
Also known as ovarian transitional cell cancerovary transitional cell carcinomatransitional cell carcinoma of ovarytransitional cell carcinoma of the ovary
Summary
Ovarian transitional cell carcinoma (MONDO:0006343) is a cancer and 21 clinical trials. Top therapeutic interventions include paclitaxel, topotecan, and gemcitabine. A subtype of ovarian carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ovarian transitional cell carcinoma |
| Mondo ID | MONDO:0006343 |
| EFO | EFO:1000435 |
| DOID | DOID:4000 |
| NCIT | C5240 |
| UMLS | C1335184 |
| MedGen | 233811 |
| GARD | 0024373 |
| Anatomy (UBERON) | UBERON:0000992 |
| Is cancer (heuristic) | yes |
Also known as: ovarian transitional cell cancer · ovarian transitional cell carcinoma · ovary transitional cell carcinoma · transitional cell carcinoma of ovary · transitional cell carcinoma of the ovary
Disease family
This is a subtype of ovarian carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › malignant epithelial tumor of ovary › ovarian carcinoma › ovarian transitional cell carcinoma
Related subtypes (8): ovarian adenocarcinoma, ovarian large-cell neuroendocrine carcinoma, ovarian squamous cell carcinoma, ovarian carcinosarcoma, ovarian small cell carcinoma, ovarian seromucinous carcinoma, undifferentiated ovarian carcinoma, familial ovarian carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 8 |
| PHASE2 | 5 |
| PHASE1 | 4 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00565851 | PHASE3 | ACTIVE_NOT_RECRUITING | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT01167712 | PHASE3 | ACTIVE_NOT_RECRUITING | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT02446600 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02502266 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer |
| NCT04575935 | PHASE3 | RECRUITING | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial |
| NCT00108745 | PHASE3 | UNKNOWN | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00262847 | PHASE3 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00719303 | PHASE3 | UNKNOWN | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00951496 | PHASE3 | COMPLETED | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT02068794 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT04739800 | PHASE2 | ACTIVE_NOT_RECRUITING | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents |
| NCT01097746 | PHASE2 | COMPLETED | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
| NCT02364713 | PHASE2 | TERMINATED | MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
| NCT02923739 | PHASE2 | TERMINATED | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT04092270 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer |
| NCT00989651 | PHASE1 | COMPLETED | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT01074411 | PHASE1 | COMPLETED | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
| NCT02111941 | EARLY_PHASE1 | COMPLETED | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT03641287 | Not specified | TERMINATED | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PACLITAXEL | 4 | 12 |
| TOPOTECAN | 4 | 4 |
| GEMCITABINE | 4 | 2 |
| OLAPARIB | 4 | 2 |
| BEVACIZUMAB | 4 | 1 |
| CEDIRANIB | 3 | 5 |
| VELIPARIB | 3 | 2 |
| EMACTUZUMAB | 3 | 1 |
| PACLITAXEL POLIGLUMEX | 3 | 1 |
| NEDISERTIB | 1 | 1 |
| S-ROLIPRAM | 0 | 1 |